Do analysts rate PPCB or VRAX?

Virax Biolabs Group has a consensus price target of $1.00, indicating a potential upside of 437.63%. Given Virax Biolabs Group's stronger consensus rating and higher probable upside, analysts plainly believe Virax Biolabs Group is more favorable than Propanc Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Propanc Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Virax Biolabs Group 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings & valuation, PPCB or VRAX?

Virax Biolabs Group has higher revenue and earnings than Propanc Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Propanc Biopharma N/A N/A -$58.92M -$24.25 N/A Virax Biolabs Group $2.99K 270.47 -$6.06M N/A N/A

Is PPCB or VRAX more profitable?

Virax Biolabs Group's return on equity of 0.00% beat Propanc Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Propanc Biopharma N/A -151.28% -109.53% Virax Biolabs Group N/A N/A N/A

Which has preferable valuation and earnings, ARTL or VRAX?

Virax Biolabs Group has higher revenue and earnings than Artelo Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Artelo Biosciences N/A N/A -$12.88M -$32.74 N/A Virax Biolabs Group $2.99K 270.47 -$6.06M N/A N/A

Is ARTL or VRAX more profitable?

Virax Biolabs Group's return on equity of 0.00% beat Artelo Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Artelo Biosciences N/A -1,600.12% -224.62% Virax Biolabs Group N/A N/A N/A

Do analysts rate VRAX or VIVS?

Virax Biolabs Group currently has a consensus target price of $1.00, indicating a potential upside of 437.63%. Given Virax Biolabs Group's stronger consensus rating and higher possible upside, research analysts clearly believe Virax Biolabs Group is more favorable than VivoSim Labs. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virax Biolabs Group 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 VivoSim Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, VRAX or VIVS?

VivoSim Labs has higher revenue and earnings than Virax Biolabs Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Virax Biolabs Group $2.99K 270.47 -$6.06M N/A N/A VivoSim Labs $140K 22.45 -$2.48M -$3.15 N/A

Which has stronger earnings & valuation, SNYR or VRAX?

Virax Biolabs Group has lower revenue, but higher earnings than Synergy CHC. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Synergy CHC $30.38M 0.10 -$12.34M -$1.40 N/A Virax Biolabs Group $2.99K 270.47 -$6.06M N/A N/A

Which has better valuation & earnings, DCOY or VRAX?

Virax Biolabs Group has higher revenue and earnings than Decoy Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Decoy Therapeutics N/A N/A -$12.52M -$106.90 N/A Virax Biolabs Group $2.99K 270.47 -$6.06M N/A N/A

Is DCOY or VRAX more profitable?

Virax Biolabs Group's return on equity of 0.00% beat Decoy Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Decoy Therapeutics N/A -395.42% -193.30% Virax Biolabs Group N/A N/A N/A

Virax Biolabs Group (VRAX) Competitors

$0.19 +0.00 (+1.09%)

As of 01:41 PM Eastern

Compare

VRAX vs. PPCB, ARTL, VIVS, SNYR, and DCOY

Should you buy Virax Biolabs Group stock or one of its competitors? MarketBeat compares Virax Biolabs Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Virax Biolabs Group include Propanc Biopharma (PPCB), Artelo Biosciences (ARTL), VivoSim Labs (VIVS), Synergy CHC (SNYR), and Decoy Therapeutics (DCOY). These companies are all part of the "pharmaceutical products" industry.

How does Virax Biolabs Group compare to Propanc Biopharma?

Propanc Biopharma (NASDAQ:PPCB) and Virax Biolabs Group (NASDAQ:VRAX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends and analyst recommendations.

Virax Biolabs Group's return on equity of 0.00% beat Propanc Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Propanc Biopharma	N/A	-151.28%	-109.53%
Virax Biolabs Group	N/A	N/A	N/A

Virax Biolabs Group has a consensus price target of $1.00, indicating a potential upside of 437.63%. Given Virax Biolabs Group's stronger consensus rating and higher probable upside, analysts plainly believe Virax Biolabs Group is more favorable than Propanc Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

8.6% of Virax Biolabs Group shares are owned by institutional investors. 28.5% of Propanc Biopharma shares are owned by company insiders. Comparatively, 45.1% of Virax Biolabs Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Propanc Biopharma has a beta of 3.48, indicating that its stock price is 248% more volatile than the broader market. Comparatively, Virax Biolabs Group has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market.

Virax Biolabs Group has higher revenue and earnings than Propanc Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Propanc Biopharma	N/A	N/A	-$58.92M	-$24.25	N/A
Virax Biolabs Group	$2.99K	270.47	-$6.06M	N/A	N/A

In the previous week, Propanc Biopharma had 5 more articles in the media than Virax Biolabs Group. MarketBeat recorded 7 mentions for Propanc Biopharma and 2 mentions for Virax Biolabs Group. Propanc Biopharma's average media sentiment score of 0.80 beat Virax Biolabs Group's score of 0.43 indicating that Propanc Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Propanc Biopharma	Positive
Virax Biolabs Group	Neutral

Summary

Virax Biolabs Group beats Propanc Biopharma on 9 of the 12 factors compared between the two stocks.

How does Virax Biolabs Group compare to Artelo Biosciences?

Artelo Biosciences (NASDAQ:ARTL) and Virax Biolabs Group (NASDAQ:VRAX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, media sentiment, profitability, risk, institutional ownership and analyst recommendations.

Virax Biolabs Group's return on equity of 0.00% beat Artelo Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artelo Biosciences	N/A	-1,600.12%	-224.62%
Virax Biolabs Group	N/A	N/A	N/A

0.9% of Artelo Biosciences shares are owned by institutional investors. Comparatively, 8.6% of Virax Biolabs Group shares are owned by institutional investors. 3.2% of Artelo Biosciences shares are owned by company insiders. Comparatively, 45.1% of Virax Biolabs Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Artelo Biosciences had 2 more articles in the media than Virax Biolabs Group. MarketBeat recorded 4 mentions for Artelo Biosciences and 2 mentions for Virax Biolabs Group. Artelo Biosciences' average media sentiment score of 0.72 beat Virax Biolabs Group's score of 0.43 indicating that Artelo Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Artelo Biosciences	Positive
Virax Biolabs Group	Neutral

Artelo Biosciences has a beta of -0.13, indicating that its share price is 113% less volatile than the broader market. Comparatively, Virax Biolabs Group has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market.

Virax Biolabs Group has higher revenue and earnings than Artelo Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artelo Biosciences	N/A	N/A	-$12.88M	-$32.74	N/A
Virax Biolabs Group	$2.99K	270.47	-$6.06M	N/A	N/A

Artelo Biosciences presently has a consensus price target of $54.00, suggesting a potential upside of 3,947.98%. Virax Biolabs Group has a consensus price target of $1.00, suggesting a potential upside of 437.63%. Given Artelo Biosciences' higher possible upside, equities research analysts plainly believe Artelo Biosciences is more favorable than Virax Biolabs Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artelo Biosciences	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Virax Biolabs Group beats Artelo Biosciences on 9 of the 12 factors compared between the two stocks.

How does Virax Biolabs Group compare to VivoSim Labs?

Virax Biolabs Group (NASDAQ:VRAX) and VivoSim Labs (NASDAQ:VIVS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends.

Virax Biolabs Group has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market. Comparatively, VivoSim Labs has a beta of 1.38, indicating that its share price is 38% more volatile than the broader market.

8.6% of Virax Biolabs Group shares are owned by institutional investors. Comparatively, 8.2% of VivoSim Labs shares are owned by institutional investors. 45.1% of Virax Biolabs Group shares are owned by company insiders. Comparatively, 2.5% of VivoSim Labs shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

VivoSim Labs has higher revenue and earnings than Virax Biolabs Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virax Biolabs Group	$2.99K	270.47	-$6.06M	N/A	N/A
VivoSim Labs	$140K	22.45	-$2.48M	-$3.15	N/A

Virax Biolabs Group currently has a consensus target price of $1.00, indicating a potential upside of 437.63%. Given Virax Biolabs Group's stronger consensus rating and higher possible upside, research analysts clearly believe Virax Biolabs Group is more favorable than VivoSim Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
VivoSim Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Virax Biolabs Group has a net margin of 0.00% compared to VivoSim Labs' net margin of -861.27%. Virax Biolabs Group's return on equity of 0.00% beat VivoSim Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virax Biolabs Group	N/A	N/A	N/A
VivoSim Labs	-861.27%	-15.51%	-11.31%

In the previous week, Virax Biolabs Group and Virax Biolabs Group both had 2 articles in the media. VivoSim Labs' average media sentiment score of 1.28 beat Virax Biolabs Group's score of 0.43 indicating that VivoSim Labs is being referred to more favorably in the news media.

Company	Overall Sentiment
Virax Biolabs Group	Neutral
VivoSim Labs	Positive

Summary

Virax Biolabs Group beats VivoSim Labs on 9 of the 13 factors compared between the two stocks.

How does Virax Biolabs Group compare to Synergy CHC?

Synergy CHC (NASDAQ:SNYR) and Virax Biolabs Group (NASDAQ:VRAX) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations.

Virax Biolabs Group has a net margin of 0.00% compared to Synergy CHC's net margin of -60.02%. Virax Biolabs Group's return on equity of 0.00% beat Synergy CHC's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synergy CHC	-60.02%	-19.51%	-30.30%
Virax Biolabs Group	N/A	N/A	N/A

8.6% of Virax Biolabs Group shares are held by institutional investors. 32.9% of Synergy CHC shares are held by insiders. Comparatively, 45.1% of Virax Biolabs Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Synergy CHC has a beta of -0.27, suggesting that its share price is 127% less volatile than the broader market. Comparatively, Virax Biolabs Group has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market.

Synergy CHC presently has a consensus target price of $6.25, indicating a potential upside of 2,947.29%. Virax Biolabs Group has a consensus target price of $1.00, indicating a potential upside of 437.63%. Given Synergy CHC's stronger consensus rating and higher probable upside, equities analysts clearly believe Synergy CHC is more favorable than Virax Biolabs Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synergy CHC	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Virax Biolabs Group has lower revenue, but higher earnings than Synergy CHC.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synergy CHC	$30.38M	0.10	-$12.34M	-$1.40	N/A
Virax Biolabs Group	$2.99K	270.47	-$6.06M	N/A	N/A

In the previous week, Synergy CHC had 10 more articles in the media than Virax Biolabs Group. MarketBeat recorded 12 mentions for Synergy CHC and 2 mentions for Virax Biolabs Group. Virax Biolabs Group's average media sentiment score of 0.43 beat Synergy CHC's score of -0.47 indicating that Virax Biolabs Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Synergy CHC	Neutral
Virax Biolabs Group	Neutral

Summary

Virax Biolabs Group beats Synergy CHC on 9 of the 14 factors compared between the two stocks.

How does Virax Biolabs Group compare to Decoy Therapeutics?

Decoy Therapeutics (NASDAQ:DCOY) and Virax Biolabs Group (NASDAQ:VRAX) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Decoy Therapeutics presently has a consensus target price of $30.00, indicating a potential upside of 385.04%. Virax Biolabs Group has a consensus target price of $1.00, indicating a potential upside of 437.63%. Given Virax Biolabs Group's higher probable upside, analysts clearly believe Virax Biolabs Group is more favorable than Decoy Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Virax Biolabs Group's return on equity of 0.00% beat Decoy Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Decoy Therapeutics	N/A	-395.42%	-193.30%
Virax Biolabs Group	N/A	N/A	N/A

Virax Biolabs Group has higher revenue and earnings than Decoy Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Decoy Therapeutics	N/A	N/A	-$12.52M	-$106.90	N/A
Virax Biolabs Group	$2.99K	270.47	-$6.06M	N/A	N/A

Decoy Therapeutics has a beta of 0.57, meaning that its share price is 43% less volatile than the broader market. Comparatively, Virax Biolabs Group has a beta of 1.26, meaning that its share price is 26% more volatile than the broader market.

11.9% of Decoy Therapeutics shares are owned by institutional investors. Comparatively, 8.6% of Virax Biolabs Group shares are owned by institutional investors. 1.7% of Decoy Therapeutics shares are owned by insiders. Comparatively, 45.1% of Virax Biolabs Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Decoy Therapeutics had 2 more articles in the media than Virax Biolabs Group. MarketBeat recorded 4 mentions for Decoy Therapeutics and 2 mentions for Virax Biolabs Group. Virax Biolabs Group's average media sentiment score of 0.43 beat Decoy Therapeutics' score of 0.37 indicating that Virax Biolabs Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Decoy Therapeutics	Neutral
Virax Biolabs Group	Neutral

Summary

Virax Biolabs Group beats Decoy Therapeutics on 8 of the 10 factors compared between the two stocks.

Get Virax Biolabs Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VRAX vs. The Competition

Export

Metric	Virax Biolabs Group	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$808K	$3.40B	$6.50B	$12.36B
Dividend Yield	N/A	2.25%	2.67%	5.67%
P/E Ratio	N/A	20.08	23.99	24.69
Price / Sales	270.47	322.83	538.03	166.93
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	0.15	8.06	10.47	6.82
Net Income	-$6.06M	$23.89M	$3.56B	$337.45M
7 Day Performance	-10.92%	2.75%	1.21%	2.49%
1 Month Performance	21.17%	0.70%	2.14%	4.37%
1 Year Performance	-78.92%	45.69%	26.24%	32.80%

Virax Biolabs Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VRAX Virax Biolabs Group	2.7537 of 5 stars	$0.19 +1.1%	$1.00 +437.6%	-79.2%	$808K	$2.99K	N/A	5	Short Interest Increase
PPCB Propanc Biopharma	1.1822 of 5 stars	$1.35 -2.2%	N/A	-98.9%	$3.14M	N/A	N/A	1	News Coverage Buyback Announcement
ARTL Artelo Biosciences	1.6604 of 5 stars	$1.30 -2.3%	$54.00 +4,053.8%	-93.7%	$3.10M	N/A	N/A	5	Gap Down
VIVS VivoSim Labs	1.43 of 5 stars	$1.18 -0.8%	N/A	-29.2%	$3.10M	$140K	N/A	20	Positive News
SNYR Synergy CHC	2.1413 of 5 stars	$0.19 -4.9%	$6.25 +3,242.2%	-90.6%	$2.97M	$30.38M	N/A	40	News Coverage Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VRAX) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Virax Biolabs Group (VRAX) Competitors

VRAX vs. PPCB, ARTL, VIVS, SNYR, and DCOY

How does Virax Biolabs Group compare to Propanc Biopharma?

Summary

How does Virax Biolabs Group compare to Artelo Biosciences?

Summary

How does Virax Biolabs Group compare to VivoSim Labs?

Summary

How does Virax Biolabs Group compare to Synergy CHC?

Summary

How does Virax Biolabs Group compare to Decoy Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRAX vs. The Competition

Virax Biolabs Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Virax Biolabs Group (VRAX) Competitors

VRAX vs. PPCB, ARTL, VIVS, SNYR, and DCOY

How does Virax Biolabs Group compare to Propanc Biopharma?

Is PPCB or VRAX more profitable?

Do analysts rate PPCB or VRAX?

Do insiders & institutionals have more ownership in PPCB or VRAX?

Which has more risk and volatility, PPCB or VRAX?

Which has preferable earnings & valuation, PPCB or VRAX?

Does the media favor PPCB or VRAX?

Summary

How does Virax Biolabs Group compare to Artelo Biosciences?

Is ARTL or VRAX more profitable?

Do insiders & institutionals hold more shares of ARTL or VRAX?

Does the media prefer ARTL or VRAX?

Which has more volatility & risk, ARTL or VRAX?

Which has preferable valuation and earnings, ARTL or VRAX?

Do analysts prefer ARTL or VRAX?

Summary

How does Virax Biolabs Group compare to VivoSim Labs?

Which has more volatility & risk, VRAX or VIVS?

Do insiders and institutionals believe in VRAX or VIVS?

Which has preferable earnings and valuation, VRAX or VIVS?

Do analysts rate VRAX or VIVS?

Is VRAX or VIVS more profitable?

Does the media prefer VRAX or VIVS?

Summary

How does Virax Biolabs Group compare to Synergy CHC?

Is SNYR or VRAX more profitable?

Do insiders and institutionals believe in SNYR or VRAX?

Which has more risk & volatility, SNYR or VRAX?

Do analysts prefer SNYR or VRAX?

Which has stronger earnings & valuation, SNYR or VRAX?

Does the media refer more to SNYR or VRAX?

Summary

How does Virax Biolabs Group compare to Decoy Therapeutics?

Do analysts recommend DCOY or VRAX?

Is DCOY or VRAX more profitable?

Which has better valuation & earnings, DCOY or VRAX?

Which has more risk & volatility, DCOY or VRAX?

Do insiders and institutionals believe in DCOY or VRAX?

Does the media favor DCOY or VRAX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRAX vs. The Competition

Virax Biolabs Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools